190197-86-5

Usage

Uses

Used in Organic Synthesis:
4-Bromo-3-(bromomethyl)benzonitrile is utilized as a building block in organic synthesis, particularly for the production of pharmaceuticals and agrochemicals. Its unique chemical structure allows for the creation of a wide range of compounds with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Bromo-3-(bromomethyl)benzonitrile is used as an intermediate in the synthesis of various drugs. Its presence in the molecular structure can contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 4-Bromo-3-(bromomethyl)benzonitrile is employed as an intermediate for the synthesis of pesticides and other crop protection agents. Its unique properties can enhance the effectiveness and selectivity of these products.
Used in Dye and Pigment Manufacturing:
4-Bromo-3-(bromomethyl)benzonitrile is also used as an intermediate in the manufacture of dyes and pigments. Its bromine-containing structure can impart specific color characteristics and improve the stability of these products.
Safety Precautions:
Due to the presence of bromine atoms, 4-Bromo-3-(bromomethyl)benzonitrile can be hazardous, and it is crucial to handle and store 4-BroMo-3-(broMoMethyl)benzonitrile with proper safety measures to prevent potential health and environmental risks.

Upstream product

• 41963-20-6 4-bromo-3-methylbenzonirtile 
• 94-36-0 dibenzoyl peroxide 
• 845616-12-8 2-bromo-5-cyanobenzoic acid 
• 905710-66-9 4-bromo-3-(hydroxymethyl)benzonitrile 

Downstream Products

• 254744-17-7 4-bromo-3-methoxymethyl-benzonitrile 
• 905710-66-9 4-bromo-3-(hydroxymethyl)benzonitrile 
• 905710-72-7 4-bromo-3-((methoxymethoxy)methyl)benzonitrile 
• 79008-77-8 2-phenylbenzofuran-5-carbonitrile 
• 128196-01-0 escitalopram 
• 144025-14-9 (+)-Desmethylcitalopram 
• 1352344-90-1 C₂₉H₃₇FN₂O₅ 

Relevant academic research and scientific papers

tBuOK-Promoted Cyclization of Imines with Aryl Halides

A transition-metal-free indole synthesis using radical coupling of 2-halotoluenes and imines via the later-stage C-N bond construction was reported for the first time. It includes an aminyl radical generation by C-H cleaving addition of 2-halotoluenes to imines via the carbanion radical relay and an intramolecular coupling of aryl halides with aminyl radicals. One standard condition can be used for all halides including F, Cl, Br, and I. No extra oxidant or transition metal is required.

Strategy for Overcoming Full Reversibility of Intermolecular Radical Addition to Aldehydes: Tandem C-H and C-O Bonds Cleaving Cyclization of (Phenoxymethyl)arenes with Carbonyls to Benzofurans

An intermolecular addition of carbon radicals enabled by a cascade radical coupling strategy is developed. It includes an intermolecular alkyl radical addition to a carbonyl group followed by an intramolecular alkoxy radical addition to haloarenes and produces substituted benzofurans in high yields. The radical nature of this reaction is explored by radical trapping experiments and EPR analysis. The mechanism is investigated by KIE experiments and control experiments. This method could provide rapid and practical access to the key intermediate of TAM-16, a safe and potent antibacterial agent for treating tuberculosis, and, therefore, is of great importance for organic synthesis and the pharmaceutical industry.

PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF HEPATITIS C VIRUS (HCV) INHIBITORS

The present invention generally relates to a process for preparation of 9-halo-3-(2-haloacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one of Formula I, which is an intermediate in the preparation of Hepatitis C Virus (HCV) inhibitors.

BORON-CONTAINING SMALL MOLECULES

Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.

IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents

A series of boron-containing benzoxaborole compounds was designed and synthesized for a structure-activity relationship investigation surrounding 7-(HOOCCH2CH2)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (1) with the goal of discovering

BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS

This invention provides novel compounds of the following formula useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Enantioenriched synthesis of Escitalopram using lithiation-borylation methodology

The asymmetric synthesis of Escitalopram has been completed using a lithiation-borylation reaction as the key step. Suitably functionalized enantioenriched carbamate (er 98:2) and boronic ester coupling partners were prepared and following deprotonation with s-BuLi and borylation, the tertiary alcohol was obtained in 42% yield and 93:7 er. The lithiation-borylation reaction was found to tolerate nitrile, benzylic alcohol and N-Boc functionalities. The tertiary alcohol was converted to Escitalopram in three further steps.